Navigation Links
CryoLife Announces Quarterly Cash Dividend for the Fourth Quarter 2013
Date:11/21/2013

ATLANTA, Nov. 21, 2013 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device Company focused on cardiac and vascular surgery, announced today that its Board of Directors has approved a quarterly cash dividend for the fourth quarter 2013 of $0.0275 per share of common stock outstanding.  The quarterly cash dividend of $0.0275 per share will be paid on December 20, 2013 to all common stockholders of record as of December 13, 2013.  The ex-dividend date for the quarterly dividend is December 11, 2013. 

CryoLife anticipates paying quarterly dividends in March, June, September, and December of each year.  Based on the number of shares currently outstanding, the Company currently expects to pay a total annual dividend of approximately $3.0 million.  These statements represent management's current beliefs and expectations and are forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. As such, they are subject to risks and uncertainties that could cause future events to deviate from current expectations, including without limitation that the declaration of future dividends and the establishment of the per share amount, record dates, and payment dates for future dividends are subject to final determination by the Company's Board of Directors, and will be dependent upon future earnings, cash flows, financial and lender requirements, the Board's evaluation of competing uses for available cash, and other factors.

About CryoLife, Inc.

Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the U.S., certain countries in Europa, and Canada.  CryoLife's CryoValve® SG pulmonary heart valve, processed using CryoLife's proprietary SynerGraft® technology, has FDA 510(k) clearance
'/>"/>

SOURCE CryoLife, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CryoLife To Host Second Central Venous Pathology Summit in 2013
2. CryoLife To Host Aortic Valve and Root Training Session
3. CryoLife Announces Quarterly Cash Dividend for the Third Quarter 2013
4. CryoLife kÞndigt erste Implantation des HeRO Transplantats in Europa an
5. CryoLife anuncia el primer implante europeo del injerto HeRO
6. CryoLife annuncia il primo impianto europeo di HeRO Graft
7. CryoLife Announces First European Implant Of HeRO Graft
8. CryoLife Reports Record Second Quarter Revenues
9. CryoLife Announces Release Date and Teleconference Call Details for 2013 Second Quarter Financial Results
10. CryoLife Enhances International Presence with Appointment of Andres Sarmiento as Latin America Sales Manager
11. CryoLife 2013 First Quarter Revenues Grew 10 Percent to a Record $35.5 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... GENEVA, Ill. , Jan. 15, 2014 The ... a Medical Fitness Center by the Medical Fitness Association, ... centers to achieve their full potential. The Cadence Fitness ... in the western suburbs and second in the Chicagoland ...
(Date:1/15/2014)...  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") ... its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), for ... Solta Medical, Inc. (NASDAQ: SLTM ) ("Solta") ...
(Date:1/15/2014)... Jan. 15, 2014  A novel wearable injector slightly larger than ... for patients to self-inject prescription drugs in the large doses ... blood diseases, autoimmune deficiencies, and genetic disorders.  ... $220B by 2018, according to analysts.   Many of these drugs ...
Breaking Medicine Technology:Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
... Inc. (Nasdaq: OPTR ) announced today the ... 3 trials in patients with Clostridium difficile ... Infectious Disease Society of America (IDSA) in Vancouver, British ... M.D., of the University of Oxford, presented combined data ...
... PARK, Kan., Oct. 22 Mid*Lands IRB, LLC is ... by the Association for the Accreditation of Human Research ... Council on Accreditation.   Located in the ... board (IRB) that protects the rights and welfare of ...
Cached Medicine Technology:Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 2Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 3Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 4Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 5Mid*Lands IRB, LLC - First Independent IRB in Kansas and the Kansas City Area Awarded Accreditation for Protecting Research Participants 2
(Date:7/9/2014)... associated with a small increased risk of prostate cancer, ... cancer according to a new study from Harvard School ... association remained even among men who received regular PSA ... be explained by diagnostic bias. It is the largest ... the link between vasectomy and prostate cancer. , The ...
(Date:7/9/2014)... CHICAGO After Susan Wakulich was told she had an ... lay ahead of her. , "I was devastated," said Wakulich, ... suburbs. "I knew this was a serious diagnosis. Then I ... trial that involved a less invasive procedure. It was something ... is participating in a multi-center U.S. clinical trial to evaluate ...
(Date:7/9/2014)... that captures heretofore hidden ways that cells are regulated, ... makes breast cancer cells more likely to metastasize. , ... in part by blocking two other proteins that are ... two disease processes could have unexpected ties. , ... of Nature , points to the possibility of ...
(Date:7/9/2014)... scientific research into the metabolism of stromal support cells ... metabolism of these cell types in the development of ... inflammatory conditions and cancer. That was the conclusion of ... Leuven in the leading journal Nature . , ... of wake-up call. The metabolism of cancer cells has ...
(Date:7/9/2014)... R.I. Researchers have found that fecal transplantation ... in immunocompromised patients. This is the result of ... in the Center for Women,s Gastrointestinal Medicine at The ... been published online in advance of print in the ... difficile , or C. diff , has increased ...
Breaking Medicine News(10 mins):Health News:Vasectomy may increase risk of aggressive prostate cancer 2Health News:New type of stent could help some brain aneurysm patients 2Health News:Protein pushes breast cancer cells to metastasize 2Health News:Protein pushes breast cancer cells to metastasize 3Health News:Wake-up call for more research into cell metabolism 2Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2
... conditions are likely to change their preferences for receiving ... to new findings. The study, which will ... in Amsterdam today (26 September 2011), suggests that different ... but this will often go unnoticed by their healthcare ...
... new study has shown that people with chronic obstructive ... are at a serious risk of developing cardiovascular disease. ... September 2011) at the European Respiratory Society,s Annual Congress ... lung function should be routinely screened for cardiovascular disease, ...
... a phase III clinical trial have shown that ... women with advanced breast cancer resistant to hormonal ... European Multidisciplinary Cancer Congress [1] that women treated ... an improved progression-free survival of nearly seven months ...
... Reporter , FRIDAY, Sept. 23 (HealthDay News) -- Many studies ... a day is heart-healthy, and much of the benefit has ... red wine called polyphenols. But a new Dutch study ... not lower blood pressure after all. Study author ...
... trial comparing tamoxifen with the aromatase inhibitor letrozole ... of time and continues to prevent breast cancer ... post-menopausal women with hormone receptor-positive early breast cancer. ... 2011 European Multidisciplinary Cancer Congress [1], in Stockholm ...
... The Netherlands: Belly fat, known clinically as central obesity, has ... study. The findings, which will be presented at the ... 2011), have shown central obesity as a risk factor for ... a number of health effects, such as diabetes and heart ...
Cached Medicine News:Health News:Study shows decisions over life-sustaining treatment are likely to change 2Health News:New evidence highlights risk of comorbidities for COPD patients 2Health News:New hope for advanced post-menopausal breast cancer patients resistant to hormonal therapy 2Health News:Antioxidants Not Behind Red Wine's Healthy Effect on Heart: Study 2Health News:Aromatase inhibitor letrozole guards against breast cancer relapse for up to 8 years 2Health News:Aromatase inhibitor letrozole guards against breast cancer relapse for up to 8 years 3Health News:Aromatase inhibitor letrozole guards against breast cancer relapse for up to 8 years 4Health News:'Belly fat' linked to development of asthma 2
... Intended for the quantitative determination ... Reaction: kinetic, lag phase of ... by linear phase of at ... nm. Linearity: 100 mg/dL (35.6 ...
For the quantitative determination of Urea Nitrogen in serum. Linearity: 80 mg/dl. Reaction measured at 340 nm....
Intended for the quantitative determination of total bilirubin in serum. Modified evelynmalloy method. Endpoint reaction. Wavelength: 555 nm. Linearity: 20 mg/dl (340 mol/l)...
... Powerwave is the first microplate spectrophotometer designed ... 7 days per week. With rugged hardware, ... Powerwave breaks the barrier of traditional spectrophotometry ... One instrument can easily read up to ...
Medicine Products: